Oncolytics offers mechanistic myeloma readout for pelareorep, but no efficacy numbers yet

Oncolytics Biotech has put out laboratory findings from an early-to-mid-stage study of its oncolytic virus pelareorep in relapsed or refractory multiple myeloma, but the disclosure contains nothing that lets outsiders put a commercial value on the programme. There are no response rates, no enrolment figures and no safety data in the material available.

The study combines pelareorep with bortezomib, dexamethasone and the PD-1 inhibitor pembrolizumab in patients whose disease has returned or stopped responding to earlier treatment. The company says sequencing of individual cells showed myeloid cells becoming better at presenting antigen, alongside a rise in CD8 effector memory T cells, which it reads as an antiviral immune response triggered by the virus.

Oncolytics also reports that the CD8 effector memory increase was larger in patients who responded than in those who did not. That is a mechanistic observation, not a clinical result, and the available material does not say how many patients were compared or how the difference was tested. Whether the marker could ever predict benefit would need confirmation in further work.

The full dataset is due as a poster, Abstract 2183, at the American Society of Hematology annual meeting on 12 December 2026. As context, myeloma is a crowded therapeutic area, so competitors and partners are likely to look for response and durability figures rather than biomarker patterns. Those details are not yet public.